Clinical trial
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of LQ036 Single-Domain Antibody Nebulization Solution in Patients With Poorly Controlled Asthma
NCT07589439 is registered in ClinicalTrials.gov with Shanghai Novamab Biopharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of LQ036 Single-Domain Antibody Nebulization Solution in Patients With Poorly Controlled Asthma
- Lead sponsor
- Shanghai Novamab Biopharmaceuticals Co., Ltd.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 30, 2025
- Completion date
- December 31, 2027
- Enrollment
- 216 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.